Kerr on Oncology
David J. Kerr, MD, is a professor of cancer medicine at the University of Oxford in Oxford, England. He is recognized internationally for his work in the research and treatment of colorectal cancer, and has published more than 400 papers. He has founded three university spin-out companies: COBRA Therapeutics, Celleron Therapeutics, and Oxford Cancer Biomarkers. In 2002, he was appointed Commander of the British Empire by Queen Elizabeth and in 2010 was elected president of the European Society for Medical Oncology.+ Add to Email Alerts
- New Research Points to a Better Biomarker for MSI mCRC
- Phase 1 Trials: Are We Using Optimal Drug Dose Schedules?
- AI in Oncology: Sorting Through Misinformation
- Health Professionals: Reducing the Risks for Nuclear War
- Recent UN Health Declarations: Clichés and Lies?
- Celebrating 75th Anniversary of the National Health Service
- Global Cancer Control: Working Together to Make a Difference
- More Expensive Alcohol Saves Lives. Will It Affect Cancer?
- Debulking Primary Disease: Does It Spur Micro-Metastases?
- Cycle of Cancer Immunity: A Primer for Oncologists
- FOxTROT Trial Sheds Light on Neoadjuvant Therapy for CRC
- Does Somatic Variation Affect ctDNA Testing?
- The End of England's Long-Term National Cancer Plan: Costing Lives?
- ESMO 2022 New Guidelines Provide 'Clear Blueprint' for Managing IO Toxicity
- Ukrainian Refugees With Cancer: Where Does the Burden Go?
- Doctors in Film: Which Movies Are Most Inspirational to You?
- Pharmacokinetically Guided Dosing: The Way Forward?
- Cancer Control in Sub-Saharan Africa: Investment Needed
- Using ctDNA to Guide Adjuvant Therapy in Stage II CRC
- Devolved Healthcare: The Benefits and Drawbacks